|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nicholson HE, Tariq Z, Housden BE,
Jennings RB, Stransky LA, Perrimon N, Signoretti S and Kaelin WG
Jr: HIF-independent synthetic lethality between CDK4/6 inhibition
and VHL loss across species. Sci Signal. 12:122019. View Article : Google Scholar
|
|
3
|
Li QK, Pavlovich CP, Zhang H, Kinsinger CR
and Chan DW: Challenges and opportunities in the proteomic
characterization of clear cell renal cell carcinoma (ccRCC): A
critical step towards the personalized care of renal cancers. Semin
Cancer Biol. 55:8–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sato Y, Yoshizato T, Shiraishi Y, Maekawa
S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki
H, et al: Integrated molecular analysis of clear-cell renal cell
carcinoma. Nat Genet. 45:860–867. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oliver GR, Hart SN and Klee EW:
Bioinformatics for clinical next generation sequencing. Clin Chem.
61:124–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xuan J, Yu Y, Qing T, Guo L and Shi L:
Next-generation sequencing in the clinic: Promises and challenges.
Cancer Lett. 340:284–295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Majer W, Kluzek K, Bluyssen H and Wesoły
J: Potential Approaches and Recent Advances in Biomarker Discovery
in Clear-Cell Renal Cell Carcinoma. J Cancer. 6:1105–1113. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoshihara K, Shahmoradgoli M, Martínez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Atkins MB, Regan M and McDermott D: Update
on the role of interleukin 2 and other cytokines in the treatment
of patients with stage IV renal carcinoma. Clin Cancer Res.
10:6342S–6346S. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Escudier B: Emerging immunotherapies for
renal cell carcinoma. Ann Oncol. 23 (Suppl 8):viii35–viii40. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M,
Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A,
et al: Tumor immune microenvironment characterization in clear cell
renal cell carcinoma identifies prognostic and
immunotherapeutically relevant messenger RNA signatures. Genome
Biol. 17:2312016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gupta S, Lee A, Hu C, Fanzo J, Goldberg I,
Cattoretti G and Pernis AB: Molecular cloning of IBP, a SWAP-70
homologous GEF, which is highly expressed in the immune system. Hum
Immunol. 64:389–401. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mavrakis KJ, McKinlay KJ, Jones P and
Sablitzky F: DEF6, a novel PH-DH-like domain protein, is an
upstream activator of the Rho GTPases Rac1, Cdc42, and RhoA. Exp
Cell Res. 294:335–344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tanaka Y, Bi K, Kitamura R, Hong S, Altman
Y, Matsumoto A, Tabata H, Lebedeva S, Bushway PJ and Altman A:
SWAP-70-like adapter of T cells, an adapter protein that regulates
early TCR-initiated signaling in Th2 lineage cells. Immunity.
18:403–414. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Canonigo-Balancio AJ, Fos C, Prod'homme T,
Bécart S and Altman A: SLAT/Def6 plays a critical role in the
development of Th17 cell-mediated experimental autoimmune
encephalomyelitis. J Immunol. 183:7259–7267. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oka T, Ihara S and Fukui Y: Cooperation of
DEF6 with activated Rac in regulating cell morphology. J Biol Chem.
282:2011–2018. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Samson T, Will C, Knoblauch A, Sharek L,
von der Mark K, Burridge K and Wixler V: Def-6, a guanine
nucleotide exchange factor for Rac1, interacts with the skeletal
muscle integrin chain alpha7A and influences myoblast
differentiation. J Biol Chem. 282:15730–15742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lazer G and Katzav S: Guanine nucleotide
exchange factors for RhoGTPases: Good therapeutic targets for
cancer therapy? Cell Signal. 23:969–979. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen S, Han Q, Wang X, Yang M, Zhang Z, Li
P, Chen A, Hu C and Li S: IBP-mediated suppression of autophagy
promotes growth and metastasis of breast cancer cells via
activating mTORC2/Akt/FOXO3a signaling pathway. Cell Death Dis.
4:e8422013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Y, Hou Y, Liu T and Lou G:
Overexpression and clinical significance of IBP in epithelial
ovarian carcinoma. Oncol Lett. 15:6604–6610. 2018.PubMed/NCBI
|
|
22
|
Zhang Z, Wang Q, Li P, Zhou Y, Li S, Yi W,
Chen A, Kong P and Hu C: Overexpression of the Interferon
regulatory factor 4-binding protein in human colorectal cancer and
its clinical significance. Cancer Epidemiol. 33:130–136. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Otsubo T, Hida Y, Ohga N, Sato H, Kai T,
Matsuki Y, Takasu H, Akiyama K, Maishi N, Kawamoto T, et al:
Identification of novel targets for antiangiogenic therapy by
comparing the gene expressions of tumor and normal endothelial
cells. Cancer Sci. 105:560–567. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liao Y, Yin G, Wang X, Zhong P, Fan X and
Huang C: Identification of candidate genes associated with the
pathogenesis of small cell lung cancer via integrated
bioinformatics analysis. Oncol Lett. 18:3723–3733. 2019.PubMed/NCBI
|
|
25
|
Leek JT, Johnson WE, Parker HS, Jaffe AE
and Storey JD: The sva package for removing batch effects and other
unwanted variation in high-throughput experiments. Bioinformatics.
28:882–883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu Z, He A, Lv T, Xu C, Lin L and Lin J:
Overexpression of P4HB is correlated with poor prognosis in human
clear cell renal cell carcinoma. Cancer Biomark. 26:431–439. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martinez-Millana A, Hulst JM, Boon M,
Witters P, Fernandez-Llatas C, Asseiceira I, Calvo-Lerma J,
Basagoiti I, Traver V, De Boeck K, et al: Optimisation of children
z-score calculation based on new statistical techniques. PLoS One.
13:e02083622018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lv W, Yu X, Li W, Feng N, Feng T, Wang Y,
Lin H and Qian B: Low expression of LINC00982 and PRDM16 is
associated with altered gene expression, damaged pathways and poor
survival in lung adenocarcinoma. Oncol Rep. 40:2698–2709.
2018.PubMed/NCBI
|
|
30
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ru B, Wong CN, Tong Y, Zhong JY, Zhong
SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An
integrated repository portal for tumor-immune system interactions.
Bioinformatics. 35:4200–4202. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng Y: Dbl family guanine nucleotide
exchange factors. Trends Biochem Sci. 26:724–732. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cook DR, Rossman KL and Der CJ: Rho
guanine nucleotide exchange factors: Regulators of Rho GTPase
activity in development and disease. Oncogene. 33:4021–4035. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jansen S, Gosens R, Wieland T and Schmidt
M: Paving the Rho in cancer metastasis: Rho GTPases and beyond.
Pharmacol Ther. 183:1–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li H, Peyrollier K, Kilic G and Brakebusch
C: Rho GTPases and cancer. Biofactors. 40:226–235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Etienne-Manneville S and Hall A: Rho
GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hall A: Rho family GTPases. Biochem Soc
Trans. 40:1378–1382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jaffe AB and Hall A: Rho GTPases:
Biochemistry and biology. Annu Rev Cell Dev Biol. 21:247–269. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chiyomaru T, Tatarano S, Kawakami K,
Enokida H, Yoshino H, Nohata N, Fuse M, Seki N and Nakagawa M:
SWAP70, actin-binding protein, function as an oncogene targeting
tumor-suppressive miR-145 in prostate cancer. Prostate.
71:1559–1567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liew PL, Fang CY, Lee YC, Lee YC, Chen CL
and Chu JS: DEF6 expression in ovarian carcinoma correlates with
poor patient survival. Diagn Pathol. 11:682016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Worthmann K, Leitges M, Teng B, Sestu M,
Tossidou I, Samson T, Haller H, Huber TB and Schiffer M: Def-6, a
novel regulator of small GTPases in podocytes, acts downstream of
atypical protein kinase C (aPKC) λ/ι. Am J Pathol. 183:1945–1959.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lazo JS, McQueeney KE, Burnett JC, Wipf P
and Sharlow ER: Small molecule targeting of PTPs in cancer. Int J
Biochem Cell Biol. 96:171–181. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Porcu M, Kleppe M, Gianfelici V, Geerdens
E, De Keersmaecker K, Tartaglia M, Foà R, Soulier J, Cauwelier B,
Uyttebroeck A, et al: Mutation of the receptor tyrosine phosphatase
PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood.
119:4476–4479. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Reichardt P, Patzak I, Jones K, Etemire E,
Gunzer M and Hogg N: A role for LFA-1 in delaying T-lymphocyte
egress from lymph nodes. EMBO J. 32:829–843. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Stirnweiss A, Hartig R, Gieseler S,
Lindquist JA, Reichardt P, Philipsen L, Simeoni L, Poltorak M,
Merten C, Zuschratter W, et al: T cell activation results in
conformational changes in the Src family kinase Lck to induce its
activation. Sci Signal. 6:ra132013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Clarke CN, Lee MS, Wei W, Manyam G, Jiang
ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, et al:
Proteomic Features of Colorectal Cancer Identify Tumor Subtypes
Independent of Oncogenic Mutations and Independently Predict
Relapse-Free Survival. Ann Surg Oncol. 24:4051–4058. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chakraborty G, Rangaswami H, Jain S and
Kundu GC: Hypoxia regulates cross-talk between Syk and Lck leading
to breast cancer progression and angiogenesis. J Biol Chem.
281:11322–11331. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mahabeleshwar GH and Kundu GC: Tyrosine
kinase p56lck regulates cell motility and nuclear factor
kappaB-mediated secretion of urokinase type plasminogen activator
through tyrosine phosphorylation of IkappaBalpha following
hypoxia/reoxygenation. J Biol Chem. 278:52598–52612. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rowshanravan B, Halliday N and Sansom DM:
CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Poprach A, Lakomý R and Büchler T:
Immunotherapy of Renal Cell Carcinoma. Klin Onkol. 30 (Suppl
3):55–61. 2017.(In Czech). View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Geissler K, Fornara P, Lautenschläger C,
Holzhausen HJ, Seliger B and Riemann D: Immune signature of tumor
infiltrating immune cells in renal cancer. OncoImmunology.
4:e9850822015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu
W, Wang Z, Wu Q, Peng H, Wei H, et al: Blockade of the checkpoint
receptor TIGIT prevents NK cell exhaustion and elicits potent
anti-tumor immunity. Nat Immunol. 19:723–732. 2018. View Article : Google Scholar : PubMed/NCBI
|
